Skip to search formSkip to main contentSkip to account menu

AN-1792

Known as: AN1792, an 1792 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Amyloid beta-Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Active immunotherapy for Alzheimer's disease
2009
2009
APOE ε4 and bapineuzumab
Therapeutic development for Alzheimer disease (AD) is in a transitional period. Neurotransmitter-based approaches to date have… 
2008
2008
Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
BackgroundNew pre-clinical trials in AD mouse models may help to develop novel immunogen-adjuvant configurations with the… 
2007
2007
Absence of (cid:1) -Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia
Objective : To describe the neuropathological and bio-chemical findings of the brain examination of a patient enrolled in the AN… 
2007
2007
AN ALTERNATIVE METHOD FOR ESTIMATING EFFICACY OF THE AN1792 VACCINE FOR ALZHEIMER DISEASE
Koepsell et al.1 suggest an alternative method for analyzing the phase 2a AN1792 studies.2,3 The original analysis compared… 
Review
2006
Review
2006
Clinical Observations with AN-1792 Using TAPIR Analyses
Clinical observations with AN-1792 using tissue amyloid plaque immunoreactivity (TAPIR) analyses established for the first time… 
Review
2004
Review
2004
Immunotherapy of Alzheimer Disease
Optimism regarding the treatment and prevention of Alzheimer disease has begun to replace the attitude of therapeutic nihilism… 
2004
2004
Characteristics of COX2 inhibitors questioned
A health watchdog agency's decision on COX2 inhibitors highlights the difference in opinion about the use of these treatments. 
Review
2004
Review
2004
[Therapy of Alzheimer disease].
Dementia is one of the most important health problems in the aging populations. The most frequent cause of it is Alzheimer's… 
2002
2002
Toxicity of β‐amyloid vaccination in patients with Alzheimer's disease
On January 18, 2002, Elan Corporation and American Home Products reported their decision to temporarily suspend dosing in a phase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)